New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 13, 2012
10:00 EDTSOHU, VMW, SDRL, RBC, HITT, INVN, XOMA, SDLP, PDLI, FCS, EMC, SGEN, REGN, NGS, BERYOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Berry Plastics (BERY) initiated with a Buy at Citigroup... Fairchild Semiconductor (FCS) initiated with a Positive at Susquehanna... Hittite Microwave (HITT) initiated with an Outperform at Wells Fargo... New Gold (NGD) initiated with an Outperform at Credit Suisse... PDL BioPharma (PDLI) initiated with a Neutral at Credit Suisse... Regal-Beloit (RBC) initiated with a Buy at Janney Capital... Regeneron (REGN) initiated with an Outperform at Credit Suisse... Seadrill Partners (SDLP) initiated with a Buy at Citigroup... Seadrill (SDRL) initiated with a Buy at Deutsche Bank... Seattle Genetics (SGEN) initiated with an Outperform at Credit Suisse... XOMA (XOMA) initiated with an Outperform at Credit Suisse... VMWare (VMW) initiated with a Hold at Craig-Hallum... EMC (EMC) initiated with a Hold at Craig-Hallum... InvenSense (INVN) initiated with a Buy at Maxim... (SOHU) initiated with an Inderweight at HSBC.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
September 30, 2015
17:34 EDTREGNExpress Scripts says many PCSK9 prescriptions denied, Reuters reports
Subscribe for More Information
11:29 EDTEMCAnalyst says key tech trend positive for EMC, negative for IBM
The adoption of platform-as-a-service will accelerate, creating more positive opportunities for EMC (EMC) and posing challenges for IBM (IBM), research firm Jefferies wrote in a note to investors today. WHAT'S NEW: The growth of PaaS will accelerate because the technology enables faster and cheaper development of apps, while the proliferation of mobile apps and the increased digitization of businesses will lead to greater adoption, Jefferies analyst James Kisner stated. PaaS usage will "explode" as companies leverage apps, becoming software makers in some ways, predicted Kisner, who noted that tech research firm IDC expects the number of apps to jump 1000% in three years. EMC's Pivotal business, which enables enterprises to analyze data produced by cloud infrastructure, could be significant as app usage surges, according to Kisner. Conversely, 50% of IBM's profits are generated by middleware that "is likely to be somewhat cannibalized by PaaS," the analyst believes. The Street's revenue estimates for IBM, which call for a decline of 2% in 2016 and little change in 2017, are overly optimistic, according to Kisner, who kept a Buy rating on EMC and an Underperform rating on IBM. PRICE ACTION: In morning trading, EMC rose 2.6% to $23.74 and IBM advanced 2% to $145.34.
09:25 EDTEMCJefferies more positive on EMC, more negative on IBM
Subscribe for More Information
06:12 EDTVMW, EMCEMC's Goulden: Breaking off VMware 'wrong thing to do,' Re/code reports
EMC (EMC) president David Goulden said his firm will try to maintain its complex corporate structure amid pressure to spin off its stake in VMware (VMW), Re/code reports. "We believe strongly that breaking up is the wrong thing to do," Goulden said in an interview at Re/code's Code/Enterprise Series event. Reference Link
September 29, 2015
10:00 EDTRBCOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: ARM Holdings (ARMH) downgraded to Neutral from Buy at Natixis... Arthur J. Gallagher (AJG) downgraded to Hold from Buy at Sandler ONeill... CareDx (CDNA) downgraded to Market Perform from Outperform at Raymond James... Carlisle (CSL) downgraded to Sector Weight from Overweight at KeyBanc... Imation (IMN) downgraded to Hold from Buy at Lake Street... Mediaset Espana (GETVF) downgraded to Underweight from Equal Weight at Barclays... New Source Energy (NSLP) downgraded to Sell from Hold at Wunderlich... Peugeot (PUGOY) downgraded to Buy from Conviction Buy at Goldman... RTL Group (RGXLY) downgraded to Equal Weight from Overweight at Barclays... Regal-Beloit (RBC) downgraded to Neutral from Buy at Buckingham... Sequenom (SQNM) downgraded to Market Perform from Outperform at William Blair... Southern Copper (SCCO) downgraded to Sector Perform at Scotia Howard Weil... TerraForm Global (GLBL) downgraded to Neutral from Overweight at JPMorgan... Verastem (VSTM) downgraded to Hold from Buy at Jefferies... Vital Therapies (VTL) downgraded to Neutral from Buy at SunTrust... Williams (WMB) downgraded to Sector Perform from Outperform at Scotia Howard Weil.
09:31 EDTEMCRe/code to hold a discussion
Subscribe for More Information
07:36 EDTRBCRegal-Beloit downgraded to Neutral from Buy at Buckingham
September 28, 2015
11:31 EDTSDRLDeutsche Bank sees bottom nearing for offshore drillers, upgrades two in space
Detusche Bank upgraded Diamond Offshore (DO) and Transocean (RIG) to Hold from Sell, saying that the companies should be boosted by upcoming reductions in the number of drilling rigs deployed by energy companies. WHAT'S NEW: As many as 180 drilling vessels may cease activity over the next 12-18 months, wrote Deutsche Bank analyst Mike Urban today. The energy sector seems to have become "more realistic" about the need to reduce supply and the offshore drilling industry is "on the cusp of a major restructuring" that should mark the bottom for valuations and pricing, he explained. Addressing the long-term outlook of deepwater drilling, Urban contended that the consensus outlook, which predicts that deepwater drilling will disappear, is incorrect. In ten years, there will be demand for 320 floating rigs, versus the 225 that are active today, Urban predicted. Over the long-term ,energy companies will have to "go where the oil is," and the oil is located in deep water, the analyst explained. He raised his price target on Diamond to $21 from $17 and on Transocean to $10 from $6. WHAT'S NOTABLE: A former executive at Petrobras (PBR) testified to receiving payments made by someone claiming to be an agent of Transocean in exchange for a rig-operation contract, linking the offshore rig contractor for the first time to the corruption probe of Brazil's state-run oil company, reported Bloomberg on September 24. The news outlet cited testimony from last month as its source for the story. Subsequently, Transocean said that it had not identified any wrongdoing by its employees vis-a-vis Petrobras and is "committed to doing business lawfully and with the highest ethical standards." PRICE ACTION: In morning trading, Diamond fell 4% to $17.62 and Transocean lost 1.75% to $12.36. OTHERS TO WATCH: Other oil and gas well drillers include Helmerich & Payne (HP), Ensco (ESV), Nabors Industries (NBR) and Seadrill (SDRL), all of which are in negative territory this morning.
07:52 EDTREGNIIR Holdings to hold a conference
Subscribe for More Information
05:18 EDTREGNRegeneron and Sanofi announce of approval of Praluent in EU
Regeneron (REGN) and Sanofi (SNY) announced that the European Commission has granted marketing authorization for Praluent for the treatment of bad cholesterol, known as low-density lipoprotein cholesterol, in certain adult patients with hypercholesterolemia. Praluent is the only EC-approved PCSK9 inhibitor that is available in two starting doses as a single 1-milliter injection once every two weeks, offering two levels of efficacy. Praluent will be available in a single-dose pre-filled pen that patients self-administer. The EC approved Praluent for the treatment of adult patients with primary hypercholesterolemia or mixed dyslipidemia as an adjunct to diet: a) in combination with a statin, or statin with other lipid-lowering therapies in patients unable to reach their LDL-cholesterol goals with the maximally-tolerated statin or b) alone or in combination with other lipid-lowering therapies for patients who are statin intolerant, or for whom a statin is contraindicated. The effect of Praluent on cardiovascular morbidity and mortality has not yet been determined.
September 25, 2015
16:17 EDTREGNOn The Fly: Top stock stories for Friday
Stocks opened with sharp gains the day after Fed Chair Janet Yellen gave some clarity to the market by suggesting the Fed will most likely raise interest rates by the end of the year. During afternoon trading, the news flow slowed and the volume lightened on the buy side, leaving the sellers with the upper hand. The Nasdaq was the first index to move into negative territory, led by broad weakness in biotech stocks, while the Dow was helped to stay in the green by a big post-earnings move higher in Nike (NKE). The averages limped into the close, leaving the market with an interesting set-up to begin next week. Outside of stock news, it was certainly a headline packed day, as Speaker of the House John Boehner announced that he will resign at the end of October, Chinese President Xi Jinping continued his U.S. visit and Pope Francis addressed the United Nations while spending a second day in New York City. ECONOMIC EVENTS: In the U.S., the third estimate of second quarter GDP showed the economy grew 3.9% quarter-over-quarter, versus expectations for the GDP growth estimate to stay at 3.7%. Personal consumption in Q2 is now believed to have grown 3.6%, up from the prior estimate of 3.1%. The final University of Michigan consumer sentiment reading for September came in at 87.2, which was down from August's 91.9 but above the expected 86.2 reading... Federal Reserve Chair Janet Yellen said during a speech at UMass Amherst last night that the central bank remains inclined to hike rates this year. Yellen's remarks were incrementally hawkish, but welcomed by the market, since they helped clarify the message the Fed delivered a week ago. Of note, the Fed chair paused multiple times toward the end of her speech and received medical attention afterward, but returned to her regular schedule later in the evening, with the bank explaining that Yellen was dehydrated after a long day but was otherwise fine. COMPANY NEWS: Nike jumped $10.23, or 8.9%, to $125.02 after Thursday night's report of better than expected earnings and futures orders prompted numerous price target hikes at Street research firms. Additionally, Sterne Agee upgraded Nike to Buy from Neutral, saying it thinks the company is benefiting from its "global grass roots engagement with its customers," which enables it to meet its customers' needs and determine to what extent it can raise prices. The firm, which thinks that the company is continuing to gain share, has a $150 price target on the athletic gear giant... Biotech stocks, which were already having a bad week, ended the week on a down note, as the iShares NASDAQ Biotechnology Index (IBB) fell 4.9%, giving it a weekly decline of about 13%. Among the biggest large-cap losers in the space were Vertex (VRTX), which fell 7%, Regeneron (REGN), which dropped 6% and Celgene (CELG), which slid 4.8%. MAJOR MOVERS: Among the notable gainers was Jabil Circuit (JBL), which advanced $2.38, or 12.2%, to $21.88 after it reported higher than expected earnings and gave guidance for its November quarter that was significantly above expectations. Also higher was Cirrus Logic (CRUS), which gained $3.90, or 14.4%, to $31.03 after tear downs of Apple's (AAPL) iPhone 6S and 6S Plus led analysts to conclude that the chipmaker appears poised to obtain more revenue from the new devices than from the previous generation of the market-leading smartphone. Among the noteworthy losers was Finish Line (FINL), which fell $4.86, or 19.6%, to $19.91 after reporting second quarter revenue that missed expectations and saying it expects adjusted earnings this fiscal year to increase in a low single to mid single digits percentage from last year. Also lower following its earnings report was smartphone and software maker BlackBerry (BBRY), which slid 7.68% to $6.49 after the company posted a second quarter loss that was steeper than analysts expected. BlackBerry also confirmed press reports that it plans to launch a new phone that uses Google's (GOOG) Android operating system instead of its own proprietary BB10 OS. Shares of Aratana Therapeutics (PETX), which dropped $6.81, or 38.97%, to $10.68 after the company said that, based on "mixed clinical and scientific results," it does not believe that canine lymphoma products AT-004 and AT-005 in their current, first-generation forms will capture the desired lymphoma market opportunity. INDEXES: The Dow rose 113.35, or 0.7%, to 16,314.67, the Nasdaq fell 47.98, or 1.01%, to 4,686.50, and the S&P 500 added/slipped 0.90, or 0.05%, to 1,931.34.
09:07 EDTREGNBayer says Eylea recommended for EU approval in additional indication
Subscribe for More Information
September 24, 2015
08:33 EDTREGNRegeneron and Icahn School of Medicine enter antibody research agreement
Regeneron and The Experimental Therapeutics Institute at the Icahn School of Medicine at Mount Sinai today announced that they have entered into an agreement with the goal of accelerating the discovery of fully human antibodies directed against therapeutic targets being researched by Mount Sinai investigators. Regeneron will provide the ETI with access to VelocImmune technology and potential financial support to use the company's proprietary antibody discovery platform to generate antibodies against targets of interest and explore potential therapeutic applications for human disease. ETI will undertake preclinical research, and Regeneron has an exclusive option to negotiate a license to the antibody for future clinical development and commercialization.
September 23, 2015
17:21 EDTEMCEMC names Laura Sen to board
Subscribe for More Information
10:26 EDTEMC, VMWEMC standstill agreement with activist expired on Sept. 1, Re/code reports
The standstill agreement between EMC (EMC) and activist investor Elliott Management expired on September 1, Arik Hesseldahl of Re/code reports, citing people familiar with the terms. EMC may have asked Elliott for an informal extension of the agreement as its board weighs its options since Elliott has yet to resume its public campaign of pushing for a breakup, Hesseldahl adds. Reference Link
07:02 EDTPDLIPDL BioPharma announces conclusion of agreement with Avinger
Subscribe for More Information
September 22, 2015
08:08 EDTVMWVMware expands relationship with SAP
VMware (VMW) announced the expansion of its relationship with SAP (SAP). SAP and VMware plan to integrate the ACE approach to enable secure, instant deployment and login of SuccessFactors and Concur mobile applications on iOS and Android devices. The ACE community also announced today 21 new members, growing more than seven-fold since its inception in March 2015.
08:08 EDTVMWVMware extends Samsung partnership to include AirWatch
Subscribe for More Information
07:29 EDTEMCEMC coverage assumed with a Buy at Goldman
Target $30.
06:21 EDTEMCEMC coverage assumed with a Buy at Goldman
Subscribe for More Information
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use